A novel oral form of salmon calcitonin improves glucose homeostasis and reduces body weight in diet-induced obese rats

Oral administration of glucagon-like peptide 1 or peptide YY 3-36 affects food intake in healthy male subjects

(2010) Robert E Steinert et al.   AMERICAN JOURNAL OF CLINICAL NUTRITION

Enhanced Amylin-Mediated Body Weight Loss in Estradiol-Deficient Diet-Induced Obese Rats

(2010) James L. Trevaskis et al.   ENDOCRINOLOGY

Hyperinsulinemia Precedes Insulin Resistance in Mice Lacking Pancreatic β-Cell Leptin Signaling

(2010) Sarah L. Gray et al.   ENDOCRINOLOGY

Lessons Learned From the Development of Oral Calcitonin: The First Tablet Formulation of a Protein in Phase III Clinical Trials

(2010) M. A. Karsdal et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Obesity punches above its weight in osteoarthritis

(2010) Richard M. Aspden   Nature Reviews Rheumatology

Brainstem mechanisms of amylin-induced anorexia

(2010) Catarina Soares Potes et al.   PHYSIOLOGY & BEHAVIOR

The effect of oral salmon calcitonin delivered with 5-CNAC on bone and cartilage degradation in osteoarthritic patients: a 14-day randomized study

(2009) M.A. Karsdal et al.   OSTEOARTHRITIS AND CARTILAGE

Pharmacokinetics and Pharmacodynamic Effects of Oral GLP-1 and PYY3-36: A Proof-of-concept Study in Healthy Subjects

(2008) C Beglinger et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Hypoglycaemia in Type 2 diabetes

(2008) S. A. Amiel et al.   DIABETIC MEDICINE

Too much of a good thing: why it is bad to stimulate the beta cell to secrete insulin

(2008) K. Aston-Mourney et al.   DIABETOLOGIA

New Drugs for Type 2 Diabetes Mellitus

(2008) Andrew J Krentz et al.   DRUGS